|

QL1706 (bispecific antibody targeting PD-1 and CLTA-4) Clinical Trials

5 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 1: 1Phase 2: 3Phase 1/2: 1

Top Sponsors

  • Xijing Hospital1
  • Sun Yat-sen University1
  • Shanghai Chest Hospital1
  • Guangzhou Medical University1
  • Fudan University1

Indications

  • Cancer5
  • Lung Cancer2
  • Consolidation Immunotherapy1
  • Limited-stage Small Cell Lung Cancer (LS-SCLC)1
  • CTLA41

Other5 trials

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Phase 2
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Phase 1
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.